ELI LILLY & Co is 285.9x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($1.072 T vs $3.75 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KNSA | LLY |
|---|---|---|
| Market cap | $3.75 B | $1.072 T |
| US-listed rank | #1625 | #10 |
| Revenue (latest FY) | $677.56M | $65.18B |
| Net income (latest FY) | $59.01M | $20.64B |
| Net margin | 8.7% | 31.7% |
| P/E (trailing FY) | 63.6 | 51.9 |
| SEC filings | 733 | 989 |
ELI LILLY & Co is 285.9x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($1.072 T vs $3.75 B).
In their latest fiscal years, Kiniksa Pharmaceuticals, Ltd. reported $677.56M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Kiniksa Pharmaceuticals, Ltd. and ELI LILLY & Co, or browse the full rankings.